Kandemirli, Sedat Giray2024-05-132024-05-132020-06Belge, G. vd. (2020). Prognostic value of pretreatment tumor-to-blood Standardized Uptake Ratio (SUR) in rectal cancer". Annals of nuclear medicine, 34(6), 432-4400914-7187https://link.springer.com/article/10.1007/s12149-020-01465-8https://hdl.handle.net/11452/41425Objectives: The prognostic value of SUV on pretreatment F-18 FDG PET/CT imaging in patients with rectal cancer is a matter of debate. SUR is of prognostic value for survival in different cancers. In this study, we aimed to examine the potential prognostic value of SUR and other parameters in pretreatment F-18 FDG PET/CT for non-metastatic rectal cancer. Methods: One hundred four non-metastatic rectal cancer patients who underwent pretreatment PET/CT between March 2012 and January 2018 were included in the study. Firstly, SUVmax, SUVmean, MTV, and TLG were calculated semi-automatically at the workstation. SUR was calculated as the ratio of tumor SUVmax to thoracic aorta blood SUVmean. Univariate Cox regression and Kaplan–Meier analysis were used to evaluate overall survival (OS), progression free survival (PFS), and local recurrence (LR). Then, multivariate Cox regression analysis, which included the parameters that were significant in the univariate analysis, was performed. Results: Multivariate Cox regression analysis revealed that SUR was a prognostic factor for PFS. Age and T stage were prognostic factors for both OS and PFS. MTV was found to be independent risk factors for OS. Conclusions: In our study, SUR was the only F-18 FDG PET/CT parameter found to be significant for PFS. The development of new parameters can increase the prognostic value of F-18 FDG PET/CT.eninfo:eu-repo/semantics/closedAccessFluorodeoxyglucose f18Positron-emission tomographyPrognosisRectal cancerSurSurvivalPositron-emission-tomographyBrain transfer constantsCell lung-cangerColorectal-cancerF-18-fdg petFdg-pet/ctVolumetric parametersGraphical evaluationRenal-failureSurvivalBiological transportDisease-free survivalFemaleFluorodeoxyglucose f18HumansMaleMiddle agedPositron emission tomography computed tomographyRectal neoplasmsRecurrenceReference standardsArticle0005262936000012-s2.0-8508344595743244034632297136https://doi.org/10.1007/s12149-020-01465-8RadiologyNuclear medicine & Medical imagingFluorodeoxyglucose F 18; Tumor Burden; DiceCapecitabineCapecitabine plus oxaliplatinFluorodeoxyglucose f 18FluoropyrimidineFluorouracilFolinic acidOxaliplatinFluorodeoxyglucose f 18AdultAgeArticleCancer prognosisCancer recurrenceCancer stagingCancer survivalFemaleGlycolysisHumanMajor clinical studyMaleMaximum standardized uptake valueMean standardized uptake valueMetabolic tumor volumeMiddle agedOverall survivalPositron emission tomography-computed tomographyPriority journalProgression free survivalRectum cancerRectum carcinomaRisk factorStandardized uptake value ratioSurvival analysisThoracic aortaBloodDisease free survivalMetabolismPathologyRectum tumorRecurrent diseaseStandardTransport at the cellular level